Piper Sandler analyst James Fish maintains Fastly (NYSE:FSLY) with a Neutral and lowers the price target from $19 to $13.
Baird Maintains Outperform on Marinus Pharma, Lowers Price Target to $24
Baird analyst Brian Skorney maintains Marinus Pharma (NASDAQ:MRNS) with a Outperform and lowers the price target from $32 to $24.